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DegradationHDL removes excess cholesterol from peripheral tissues and delivers it to the liver and steroidogenic tissues via
selective lipid uptakewithout catabolism of the HDL particle itself. In addition, endocytosis of HDL holo-particles
has been debated for nearly 40 years. However, neither the connection between HDL endocytosis and selective
lipid uptake, nor the physiological relevance of HDL uptake has been delineated clearly. This review will focus
on HDL endocytosis and resecretion and its relation to cholesterol transfer. Wewill discuss the role of HDL endo-
cytosis in maintaining cholesterol homeostasis in tissues and cell types involved in atherosclerosis, focusing on
liver, macrophages and endothelium. We will critically summarize the current knowledge on the receptors me-
diating HDL endocytosis including SR-BI, F1-ATPase and CD36 and on intracellular HDL transport routes. Depen-
dent on the tissue, HDL is either resecreted (retro-endocytosis) or degraded after endocytosis. Finally, ﬁndings on
HDL transcytosis across the endothelial barrier will be summarized. We suggest that HDL endocytosis and
resecretion is a rather redundant pathway under physiologic conditions. In case of disturbed lipid metabolism,
however, HDL retro-endocytosis represents an alternative pathway that enables tissues to maintain cellular cho-
lesterol homeostasis.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
High-density lipoprotein (HDL) exertsmultiple actions onmetabolic
homeostasis and thereby beneﬁcially impacts atherosclerosis, thrombo-
sis, inﬂammation, and glucose homeostasis. Importantly, HDL removes
excess cholesterol from peripheral tissues and cells. These cells include
macrophage foam cells, which are directly involved in atherosclerotic
plaque formation. HDL then transports this cholesterol to the liver for
disposal into the bile. This process of peripheral cholesterol efﬂux to
HDL and delivery to the liver is termed reverse cholesterol transport
(RCT) and is important for the anti-atherogenic properties of HDL.
Thus, high plasma HDL cholesterol levels are generally associated with
reduced risk for cardiovascular diseases [1,2].
Recent studies suggest that HDL is not a mere transport vehicle for
lipids, but is also a carrier of non-lipid cargo such as microRNAs [3].
Further, HDL can inﬂuence cellular signaling by binding to its cell
surface receptors. Hence, the complexity of HDL metabolism is still
incompletely understood, which also holds true for our knowledge on
the transfer of lipids between HDL and target cells. This is in contrast
to our extensive knowledge on the metabolism of low-densityry, Center for Pathobiochemistry
rasse 10, 1090 Vienna, Austria.
Stangl).
V. Open access under CC BY license.lipoprotein (LDL): LDL bound to the LDL receptor (LDL-R) is internalized
via clathrin-coated pits, which fuse with early sorting endosomes. After
dissociation from its receptor, themajority of LDL particles are delivered
to late endosomal compartments for hydrolysis of lipids and protein
degradation [4]. Free cholesterol can then exit late endosomes towards
the endoplasmic reticulum or the plasma membrane. HDL metabolism,
however, is more complex with regard to the cholesterol transport
routes and HDL binds to a variety of cells with varying degrees of spec-
iﬁcity. Accordingly, a number of proteins and receptors have been
described to bind HDL. After receptor binding, HDL transfers lipids to
cells predominantly by selective lipid uptake without catabolism of
the particle [5]. In addition, an alternative pathway comprising endocy-
tosis of whole HDL particles followed by resecretionwas observedmore
than 40 years ago. However, neither the connection between HDL en-
docytosis and selective lipid uptake, nor the physiological relevance of
HDL uptake is fully clariﬁed.
In this review, we will summarize receptors and mechanisms for
HDL endocytosis and resecretion focusing on liver, endothelial cells
and macrophages as central tissues in atherosclerosis development.
2. HDL endocytosis and resecretion
Even though HDL endocytosis was described in themid-seventies of
the last century [6], the relevance of HDL endocytosis for HDL metabo-
lism is still under debate and awaits its complete elucidation. Detailed
analysis of HDL endocytosis was ﬁrst described by Bierman, Stein and
Stein in rat aortic smooth muscle cells. The authors suggested that
HDL catabolism is low. Instead, they reported regurgitation of non-
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resecretion was described in macrophages by two independent studies
of Alamet al. and Schmitz et al. [8,9]. In 1990DeLamatre and co-workers
demonstrated retro-endocytosis of iodinated HDL particles in a rat liver
cell line [10]. However, the receptors involved in HDL binding were not
identiﬁed at this time.
It was not until 1996 that scavenger receptor class B, type I (SR-BI)
was cloned and characterized as an HDL receptor by the group of
Krieger [11,12]. Its human ortholog CLA-1 was described by Calvo and
Vega [13]. The main function of SR-BI is selective cholesteryl ester
uptake of HDL derived lipids by the liver and steroidogenic tissues
[14]. Indeed, SR-BI plays a crucial role in cholesterol homeostasis and
reverse cholesterol transport: Hepatic SR-BI over-expression increases
clearance of plasma cholesterol inmice [15–17] and reduces atheroscle-
rosis [18,19]. In contrast, loss of hepatic SR-BI results in elevated plasma
cholesterol levels leading to atherosclerosis [20]. In humans, a low
abundance mutation in SR-BI leads to increased plasma cholesterol
and impaired steroid hormone synthesis, further underlining the im-
portance of this receptor in lipid metabolism [21].
The transport of lipids from HDL to SR-BI is generally thought
to occur via selective cholesteryl ester uptake, where only the lipid
load of HDL is transferred without concomitant catabolism of the HDL
particle itself [5,22–24]. In addition, SR-BI is a bonaﬁde endocytic recep-
tor as it mediates the internalization of lipopolysaccharides and facili-
tates hepatitis C virus entry [25–27]. Therefore, it is well conceivable
that SR-BI also mediates HDL endocytosis. This connection was ﬁrst
described by the group of Tall: Their experiments in polarized hepato-
cytes and kidney cells showed that SR-BI mediates HDL transport to
the endosomal recycling compartment and apical membrane regions
[28]. Studies in our lab showed concomitant endocytosis of SR-BI and
HDL which was followed by particle resecretion. HDL resecretion
could be linked to cholesterol efﬂux, since resecreted HDL particles
were enriched in cellular cholesterol [29].
Endocytosis and resecretion is not limited to HDL, but instead occurs
with almost all lipoprotein classes: Similar to HDL endocytosis and
resecretion, uptake and resecretion was described for LDL as well as
Lp(a). It is estimated that approximately 20% of endocytosed LDLTable 1
HDL endocytosis in tissue culture.




Primary hepatocytes Liver Mouse
Primary hepatocytes Liver Mouse
Hepa1-6 Liver Mouse
Non-parenchymal liver cells Liver Mouse
FU5AH Liver Rat
Aortic smooth muscle cells Endothelium Rat
Aortic endothelial cells Endothelium Rat




Peritoneal macrophages Macrophage Mouse
Monocyte-derived macrophages Macrophage Human
THP-1 monocyte/macrophage Macrophage Human




3T3-L1 adipocytes Adipocytes Human
Trophoblasts Placenta Human
BeWO Placenta Human




⁎ Röhrl, Fruhwürth, Srisen, Winter, Neumüller and Stangl, unpublished data.escapes lysosomal degradation [30–32]. Additionally, recycling of apoE
is well described [for review: [33]]. ApoE derived from LDL and
triglyceride-rich particles are resistant to degradation and are
resecreted. A functional role for apoE recycling is implicated in the gen-
eration of apoE-rich HDL particles as well as cholesterol efﬂux [34–36].
By now, HDL endocytosis has been shown to occur in cell lines orig-
inating from various tissues (summarized in Table 1). In addition, HDL
endocytosis has been observed in a variety of species including humans,
rodents and even insects and crustaceans [37]. This suggests that HDL
endocytosis is a virtually ubiquitous process. This excludes erythrocytes,
where cholesterol exchange with lipoproteins is considered a passive
process without participation of lipoprotein receptors [38,39].
3. Intracellular HDL trafﬁcking and lipid exchange
While LDL endocytosis is known to occur via clathrin-coated pits [40],
it is under debate if HDL endocytosis is a clathrin-dependent or indepen-
dent process. Inhibition of clathrin-mediated endocytosis inhibited LDL
internalization, but not HDL uptake suggesting clathrin-independent
mechanisms in hepatocytes and SR-BI over-expressing CHO cells [28].
Caveolae are specialized bulb-shaped surface pits enriched in cholesterol
containing caveolin and cavin proteins and are implicated in a variety of
physiological processes including cell signaling and endocytosis. Interest-
ingly, caveolin deﬁciency severely affects lipid homeostasis [41]. SR-BI
was reported to preferentially localize to caveolae and not clathrin-
coated pits in CHO cells over-expressing SR-BI [42]. In contrast, SR-BI is
localized in rafts devoid of caveolin-1 in HepG2 cells [43]. In line with
this observation, HDL is efﬁciently endocytosed via clathrin-coated pits
in HepG2 cells, a cell line devoid of plasma membrane caveolae [44,45].
HDL endocytosis is also clathrin-mediated in Caco-2 cells [46]. Indeed,
the caveolar density remarkably differs in different tissues. Caveolae are
merely detectable in the kidney, whereas they make up to 50% of the
plasma membrane surface in endothelial cells and adipocytes [41]. As
HDL endocytosis seems to be a ubiquitous process, we suggest that
caveolae are no pre-requisite for HDL endocytosis, although the presence
of caveolae might account for a favorable environment to enhance HDL
endocytosis.Ref. Remark
[44,45,71,119,120]
[49,50] Polarized HepG2 cells
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[122] In-vitro model for blood–brain-barrier
[29,52,53,56]
[61] Degrade HDL efﬁciently
[48]
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HDL endocytosis using different methodologies: Using ultrasensitive
ﬂuorescence microcopy in SR-BI over-expressing cells we found that
HDL is endocytosed in clusters of approximately 10particles. HDL clusters
are rapidly transported towards the Golgi-apparatus (v = 0.52 μm/s), a
process requiring functional microtubules [47]. By means of combined
light and electron microscopy, we further showed a central role of
multivesicular bodies – intermediate organelles between early and
late endosomes – in HDL endocytosis in HepG2 cells. HDL accumulated
in multivesicular bodies rather slowly with a peak labeling after three
hours. Further studies suggest that HDL taken up by HepG2 and COS-7
cells is transported to two intracellular pools: A rapid-turnover
retroendocytotic pool (half-life: 3.8 min) and a slow-turnover pool
that is eventually further transported to lysosomes for degradation
[48]. These results are in close agreement with studies by WüstnerFig. 1. Putative contributions of HDL endocytosis and resecretion to RCT. ApoA-I is secreted by
exert athero-protective effects, apoA-I and HDL have to be transported tomacrophage foam cell
cells, whereas SR-BI, ABCG1 and ecto-F1-ATPase facilitate HDL transport. Excessmacrophage fre
endocytosis was shown to mediate cholesterol efﬂux. ABCG1 mainly seems to have a role in in
lymphatics and the vasa vasorum and is transported back to the liver. Here, SR-BI transfers cho
HDL binding site under the control of ecto-F1-ATPase and P2Y13 are discussed to mediat
the endosomal recycling compartment (ERC) and resecreted or transported to multivesicular
endocytosis, HDL exchanges cholesterol with hepatocytes. Cholesterol is then either used for th
sion to bile-acids. Abbreviations: FC (free cholesterol); CE (esteriﬁed cholesterol); apoA-I (apol
ABCA1 (ATP-binding cassette transporter A1); ABCG1 (ATP-binding cassette transporter G1); Cand colleagues, who likewise described a rapid turnover HDL recycling
pool (half-life: 6.9 min) in polarized hepatocytes which likely repre-
sents the endosomal recycling compartment [49,50]. HDL transport to
the ERC is consistent with ﬁndings by Silver et al. [28]. In addition to
this rapid-turnover ERC pool, we propose that multivesicular bodies
represent the slow-turnover pool for HDL endocytosis (Fig. 1) [44].
Although the intracellular trafﬁcking during HDL endocytosis has
been characterized in many aspects, it is still unclear, if endocytosis is
deﬁnitely necessary for selective lipid uptake. Several lines of evidence
suggest that HDL endocytosis is not required for selective uptake:
Liposomes containing puriﬁed SR-BI are sufﬁcient for selective CE uptake
[51]. Moreover, blocking of HDL endocytosis by different experimental
approaches does not interfere with selective uptake [52,53]. Further,
HDL is not endocytosed by luteinized ovaries which require high
amounts of cholesterol for steroid hormone synthesis [54]. In contrast,the liver and intestine (not shown here) and acquires phospholipids and cholesterol. To
s through endothelial cells. ABCA1 is necessary for apoA-I transcytosis through endothelial
e cholesterol is transported to apoA-I by ABCA1 or to HDL by SR-BI. In addition, HDL retro-
tracellular cholesterol trafﬁcking. Cholesterol enriched HDL then leaves the plaque via the
lesterol to hepatocytes by selective lipid uptake. In addition, SR-BI, CD36 and a low afﬁnity
e HDL holo-particle uptake. After endocytosis, HDL is either rapidly recycled through
bodies (MVBs). HDL degradation in lysosomes is limited and occurs rather slowly. During
e formation of new lipoproteins or secreted into the bile directly or indirectly after conver-
ipoprotein A-I); HDL (high-density lipoprotein); SR-BI (scavenger receptor class B, type I);
D36 (cluster of differentiation 36).
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lesterol exchange between HDL and hepatocytes [28,55]. Interestingly,
SR-BII, a splicing variant of SR-BI, was described tomediate endocytosis
of HDL. SR-BII over-expressionwasmore efﬁcient in enhancingHDL up-
take, whereas over-expression of SR-BI wasmore efﬁcient in increasing
selective uptake [56]. This again suggests that selective lipid uptake is
distinct from HDL endocytosis. However, differences between murine
and human SR-BI have been reported: Selective uptake mediated by
expression of CLA-1, the human analog of SR-BI, relies on endocytosis,
whereas selective uptake mediated by murine SR-BI does not [57].
It is thus unclear if HDL endocytosis is essentially required for selec-
tive uptake. However, it is clear that cholesterol exchange occurs during
endocytosis, as several reports suggest modiﬁcation of the HDL particle
after endocytosis: In SR-BI overexpressing cells HDL size ismore hetero-
geneous after resecretion, indicating HDL particle modiﬁcation during
retro-endocytosis [29]. In hepatocytes, resecreted HDL was depleted
in free and esteriﬁed cholesterol which suggests selective lipid uptake
during endocytosis [55]. In contrast, HDL resecretion from cholesterol-
laden macrophages results in secretion of enlarged, cholesterol enriched
HDL [9]. Thus, the cellular cholesterol status might determine if HDL is
cholesterol loaded or depleted during retro-endocytosis.
4. HDL catabolism
While the majority of LDL is catabolized and degraded in lysosomes,
degradation of HDL is generally hard to quantify. In human ﬁbroblasts,
degradation of HDL less than 5% compared to LDL [58] and measurable
HDL degradation is limited to certain cell types. Among these, placenta
trophoblast cells are an interesting example displaying considerable
HDL degradation. Trophoblasts represent the contact zone between
maternal and fetal tissue and their cholesterol handling is especially in-
teresting as the growing embryo most likely depends on the supply of
maternal cholesterol, primarily in the ﬁrst trimester [59]. In ﬁrst trimes-
ter trophoblasts, both HDL degradation and selective uptake from HDL
are high. In term trophoblasts, HDL degradation and selective uptake
are decreased, but still elevated compared to other tissues [60]. Tropho-
blasts are thus capable of dismantling large amounts of HDL, probably to
meet the high cholesterol requirements of the growing embryo. Our in-
vestigations provide evidence for a similar HDL degrading mechanism
in a subclone of CHO7 cells, whichwas adapted to grow under low cho-
lesterol conditions. We described that HDL degradation in both CHO7
and placenta BeWo cells was only partially blocked by chloroquine,
indicating a mechanism distinct from lysosomal degradation, which is
typical for LDL catabolism [61]. Instead, HDL degradation involved
lipases and proteoglycans and probably did not occur intracellularly.
Indeed, a role in HDL catabolism has been attributed to lipases, as both
endothelial lipase and hepatic lipase contribute to HDL remodeling,
which alters the clearance from the circulation by liver and kidney
[62,63].
The liver as a central organ in lipoprotein metabolism does not only
mediate selective CE uptake from HDL, but also HDL endocytosis and
degradation. HDL degradation in hepatocytes seems to be regulated
by leptin and is impaired in ob/ob mice [55]. Hepatic HDL catabolism
is not mediated by SR-BI, as SR-BI-deﬁcient mice show no defect in
HDL catabolism [64,65]. Further, SR-BI-mediated retro-endocytosis in
murine hepatocytes was independent of HDL degradation [28], which
appears to be mediated by a different receptor that remains to be iden-
tiﬁed. The β-chain of ATP synthase (ecto-F1-ATPase; see below), is a
possible candidate mechanism facilitating HDL degradation. The inde-
pendence of HDL degradation of SR-BI makes inhibition of HDL degra-
dation a putative therapeutic strategy for raising HDL levels without
concomitant inhibition of cholesterol clearance from plasma by selec-
tive uptake.
In contrast to the liver, the kidney is generally not regarded as a
central organ in lipoprotein metabolism, because lipoproteins are too
large to pass the glomerular ﬁltration barrier. However, an importantrole is attributed to the kidney in apoA-I catabolism. The role of the
kidney in lipid metabolism as well as the function of the HDL receptors
cubilin and megalin are excellently reviewed elsewhere [66].
Taken together, HDL degradation occurs in metabolically highly
active tissues and in cases, where extracellular cholesterol is limited. It
would be interesting to study HDL degradation in malignant tumors,
as they might rely on high amounts of exogenous cholesterol for prolif-
eration. Indeed, SR-BI expression correlates with the degree of malig-
nancy in melanoma cells (Mikula, Röhrl and Stangl, unpublished
data), suggesting an increased demand for cholesterol in malignant
metastatic tumors.
5. HDL endocytosis in tissues relevant to atherosclerosis
5.1. Liver
The liver is a complex organ composed of various cell types of paren-
chymal (hepatocytes) and non-parenchymal (Kupffer cells, endothelial
cells, stellate cells) origin. Besides nascentHDL formation, the liver plays
a major role in the clearance of HDL derived cholesterol. After injection
of radiolabeled HDL, 22% of liver associated HDL was associated with
Kupffer and endothelial cells, suggesting the importance of these cell
types for HDL metabolism [67]. In hepatocytes, HDL-cholesterol can be
secreted into the bile, converted to bile acids, or secreted via newly syn-
thesized lipoproteins. It has been suggested that HDL and not LDL is the
primary source of bile-cholesterol in humans [68]. Consistent with the
important role of HDL in reverse cholesterol transport – i.e. the trans-
port of macrophage cholesterol to the feces via biliary excretion –
hepatic SR-BI over-expression increases macrophage reverse cholester-
ol transport [69]. SR-BI is expressed at both the basolateral (sinusoidal)
and the apical (bile-canalicular)membrane inmurine liver [15]. InWIF-
B cells, a model for polarized hepatocytes, SR-BI distribution between
the basolateral and apical membrane is regulated by the cellular choles-
terol status [70]. This polarized distribution is consistent with SR-BI
being a receptor for basolateral to apical cholesterol transport into the
bile. Whether SR-BI mediates biliary cholesterol secretion via holo-
particle uptake, however, is under debate. It was shown that SR-BI
mediates HDL endocytosis in polarized HepG2 cells. However, free
cholesterol rapidly dissociated from HDL and was transported to the
apical bile-canalicular membrane independent of HDL [50]. In contrast,
Bodipy-CE as a marker for esteriﬁed cholesterol was transported to the
bile-canalicularmembrane concomitantlywith HDL in polarized prima-
ry hepatocytes [28]. These conﬂicting results can be rationalized by dif-
ferent cellular trafﬁcking of free and esteriﬁed cholesterol [71]. Probably
intracellular HDL trafﬁcking is not important for amphiphilic free
cholesterol transport to bile-canaliculi, because free cholesterol rapidly
dissociates from the HDL particle and is efﬁciently transported by
non-vesicular mechanisms.
In contrast to these in-vitro studies in SR-BI over-expressing cells,
SR-BI knockout mice display unchanged holo-HDL uptake into the
liver, whereas selective lipid uptake is considerably diminished [72].
This argues against a role for SR-BI in hepatic HDL uptake. In line with
a minor role of SR-BI in hepatic HDL endocytosis is the extensive work
of Laurent Martinez on an SR-BI-independent mechanism of HDL inter-
nalization in hepatic cells in-vitro and in-vivo: Thismechanism requires
apoA-I binding to a high afﬁnity receptor identiﬁed as the cell surface
expressed β-chain of ATP synthase (ecto-F1-ATPase), which is normally
localized in the inner mitochondrial membrane [73]. ApoA-I binding to
ecto-F1-ATPase induces the hydrolysis of ATP to ADPwhich in turn acti-
vates HDL endocytosis by a low afﬁnity receptor that remains to be
identiﬁed (Fig. 1). This endocytosis is clathrin-mediated and depen-
dents on the activation of the purinergic receptor P2Y13 by the generat-
ed ADP [74]. Indeed, HDL endocytosiswas found to be dependent on the
extracellular ADP concentration and on enzymes modulating these
levels [75]. Further characterization of this pathway showed its depen-
dence on the GTPase signaling as well as cytoskeletal reorganization
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ﬁrmed in-vivo: P2Y13-deﬁcient mice exhibited decreased hepatic HDL
and cholesterol uptake as well as decreased bilary cholesterol secretion
and total macrophage-to-feces RCT [77]. Thus, P2Y13 is putative thera-
peutic target as a regulator of hepatic HDL endocytosis [78]. Besides
the liver, ecto-F1-ATPase plays a role in HDL transcytosis in endothelial
cells (see below).
Another receptor for hepatic holo-HDL particle uptake is scavenger
receptor cluster of differentiation 36 (CD36), as recently reported by
Rinninger's group [79]. CD36 shows a high degree of sequence homology
in its extracellular domain compared to SR-BI. CD36 is a high afﬁnity HDL
receptor; in addition, CD36 has a broad spectrum of ligand as it is know
from SR-BI. Given the high homology it is not surprising that CD36 also
mediates selective lipid uptake from HDL, although less efﬁciently than
SR-BI [80,81]. Moreover, CD36 promotes HDL endocytosis, especially in
the liver [79]. HDL uptake by CD36 was shown in both hepatocytes and
non-parenchymal liver cells. Interestingly, non-parenchymal liver cells
showedhigherHDLholo-particle uptake thanhepatocyteswhennormal-
ized to cell protein.
5.2. Macrophages
Macrophages play a crucial role in the pathogenesis of atherosclero-
sis. Endothelial inﬂammation leads to recruitment and invasion of
monocytes/macrophages which excessively internalize modiﬁed lipo-
proteins. Excess cholesterol uptake triggersmacrophage foam cell forma-
tion and pronounced inﬂammatory responses. Subsequent accumulation
of cells, lipid andmatrix leads to necrotic breakdown of some lesions and
thrombosis [82]. Nascent andmatureHDLparticles can accept cholesterol
from macrophages in atherosclerotic lesions and thereby counteract
foam cell formation (Fig. 1). Major cholesterol efﬂux pathways include
aqueous diffusion as well as ABCA1, ABCG1 and SR-BI-dependent pro-
cesses [83]. If HDL endocytosis and resecretion also contribute to macro-
phage cholesterol homeostasis, remains to be clariﬁed (this question is
also addressed by a review article by Cavelier and colleagues [84]).
HDL uptake and resecretion in cholesterol-laden mouse peritoneal
macrophages was the topic of one of the ﬁrst reports of HDL retro-
endocytosis [8]. Subsequent to receptor-mediated binding, HDL was
internalized and transported into endosomes as demonstrated using
gold-labeled HDL. HDL containing endosomes did not fuse with lyso-
somes and consistently, degradation was limited. Instead, HDL contain-
ing compartments were found to interact with lipid droplets, which
might lead to direct exchange of cholesterol from lipid droplets to
HDL. In this study, HDL2 showed a higher uptake thanHDL3 [8]. In a sub-
sequent report, Alam and colleagues conﬁrmed enhanced internaliza-
tion of apoE-free HDL in human monocyte-derived macrophages upon
cholesterol loading. They found internalized HDL to be resecreted as
larger ApoE-containing HDL2-like particles and hypothesized that HDL
resecretion facilitates removal of excess cholesterol from cells [9].
More recently, we have also described HDL endocytosis and resecretion
in THP-1 monocytes/macrophages [29]. In contrast, two studies report
that HDL is not taken up in mouse peritoneal or RAW macrophages
[85,86]. Although it is still unclear, if HDL retro-endocytosis contributes
to cholesterol efﬂux, retro-endocytosis of free apoA-I might be impor-
tant for cholesterol efﬂux [86,87]. Candidate receptors for HDL endocy-
tosis in macrophages are the scavenger receptors SR-BI, CD36 and SR-A,
which bind a broad spectrum of ligands as well as ABCG1, although the
presence of this receptor at the plasmamembrane has been questioned
recently [88].
5.3. Endothelium
Interactions of lipoproteins with the vascular endothelium play a
critical role in lipid homeostasis and atherosclerosis: First, endothelial
cells mediate lipolysis of triglyceride-rich lipoproteins. Second, vascular
tone and endothelial integrity can be regulated by lipoproteins [forreview: [89]]. Third, lipoproteins as well as monocyte/macrophages
have to pass the endothelium to interact with atherosclerotic lesions.
HDL can pass the endothelial barrier more easily than VLDL and LDL,
presumably due to its smaller size [90]. HDL is considered to be actively
transported through endothelial cells by transcytosis, which involves
apical endocytosis, intracellular trafﬁcking and basolateral exocytosis.
In arteries, HDL transcytosis only occurs from the plasma towards the
intima and not in the reverse direction. Instead, HDL leaves the intima
via the vasa vasorum and the lymphatics [91]. Recently, the important
role of the lymphatics in removal of HDL from plaques and RCT was
directly demonstrated [92].
Extensive work in the group of von Eckardstein revealed that both
SR-BI and ABCG1 mediate HDL transcytosis in polarized bovine aortic
endothelial cells (Fig. 1) [93]. This group showed a role for ecto-F1-
ATPase in regulating HDL transcytosis [94]. If ecto-F1-ATPase is causally
involved in SR-BI andABCG1mediatedHDL endocytosis, is not yet prov-
en. Instead, HDL transcytosis through endothelial cells might involve
several redundant receptors since co-silencing of SR-BI and ABCG1
reduced HDL transcytosis by 30% only [93]. This strongly suggests in-
volvement of other factors inHDL transcytosis. Given the high abundance
of caveolae in endothelial cells, their contribution to HDL transcytosis
seems plausible. However, a role of caveolae has so far only been
shown in the transendothelial transport of LDL [95]. Interestingly, over-
expression of endothelial caveolin-1 leads to enhanced atherosclerosis
[96] which could be interpreted as a result of increased LDL transcytosis
resulting in enhanced foam cell formation.
Glycosylphosphatidylinositol-anchored high density lipoprotein-
binding protein 1 (GPIHBP1) was initially described as an HDL receptor
and is highly expressed in endothelial cells in-vivo [97]. However,
GPIHBP1 knockout mice have major defects in the lipolysis of triglycer-
ide lipoproteins and not in HDLmetabolism [98].Moreover, GPIHBP-1 is
not expressed in large artery endothelial cells, even though the large
arteries display HDL transcytosis. This suggests that GPIHBP-1 does
not mediate HDL transcytosis in vascular endothelial cells.
While vascular endothelial cells are studied extensively in terms of
HDL transcytosis, HDL transport through lymphatic endothelial cells
has been largely neglected previously. A recent report showed that lym-
phatic endothelial cells express ABCA1 and SR-BI, but not ABCG1 [92].
This study revealed that cholesterol removal from atherosclerotic
plaques requires active transport of HDL through lymphatic endothelial
cells, which is mediated by SR-BI.
5.4. Adipose tissue
Adipose tissue is the major storage site for triglycerides and thus
plays a central role in energy metabolism. In addition, it is the largest
reservoir for free cholesterol and a direct modulator of cholesterol
metabolism: Adipocyte ABCA1 mediates cholesterol efﬂux in-vitro
[99] and consistently, adipose tissue signiﬁcantly contributes to HDL
biogenesis in-vivo [100]. In addition, adipose tissue is involved in the
clearance of HDL derived cholesterol from the circulation, which is me-
diated by SR-BI [101,102]. HDL endocytosiswas described in adipocytes,
but its signiﬁcance is unclear. Like in other cell types, selective CEuptake
exceeds holo-particle uptake in adipocytes [103,104]. Adipocytes
express ecto-F1-ATPase and its expression increases during adipocyte
differentiation [105]. Adipocyte ecto-F1-ATPase mediates endocytosis
and resecretion of free apoA-I. However, this apoA-I recycling is not
accompanied by cholesterol efﬂux and its physiological function is
unknown yet [106]. If ecto-F1-ATPase is also involved in the regulation
of HDL endocytosis remains to be investigated.
5.5. Platelets
Platelets are directly involved in atherosclerotic plaque formation
and thrombosis. As HDL cholesterol levels are inversely related to
thrombosis risk, the interaction of HDLwith platelets is under extensive
1631C. Röhrl, H. Stangl / Biochimica et Biophysica Acta 1831 (2013) 1626–1633investigation [107]. Platelets express SR-BI and SR-BI knockout
mice display defects in platelet structure and function [108]. However,
this effect was largely attributed to dyslipidemia in these mice rather
than to the absence of the receptor in platelets per se [109,110]. Evi-
dence for a direct role of platelet SR-BI was provided recently in a
study which identiﬁed HDL associated phospholipids as important
modulators of the anti-thrombotic action of HDL [111]. Another study
suggests that the reduction of platelet membrane cholesterol by efﬂux
to reconstituted HDL can be utilized as a therapeutic approach to inhibit
platelet activation [112]. However, the effects of HDL on platelet activa-
tion were generally attributed to alterations in cell signaling and a role
for HDL endocytosis has not been investigated yet.
6. Conclusions and perspectives
Despite the fact that HDL endocytosis has been known for more
than 40 years, its physiological relevance is still under debate. HDL en-
docytosis does not seem to be a major contributor to maintain cellular
cholesterol homeostasis. It is generally accepted that selective lipid up-
take exceeds HDL protein uptake and is highly efﬁcient [5]. However,
various pieces of evidence point towards a redundant function of HDL
holo-particle uptake in cases where normal mechanisms to maintain
cellular cholesterol homeostasis are disturbed.
In SR-BI knockout mice, HDL endocytosis in adrenals is enhanced,
suggesting a compensation for reduced selective lipid uptake [72].
Further evidences for HDL endocytosis as a redundant pathway come
from our ﬁndings in cells derived from patients with Niemann–Pick
disease, where the LDL-receptor pathway and late endosomal choles-
terol trafﬁcking are impaired. In ﬁbroblasts from these patients, HDL
retro-endocytosis is still functional in maintaining cellular cholesterol
homeostasis [113]. Similarly, HDL and LDL resecretion mediates choles-
terol efﬂux in ﬁbroblasts from patients with Tangier disease, where
ABCA1 function and cholesterol efﬂux to apoA-I are defective (Neuhofer
and Stangl, unpublished data).
In case of low cholesterol availability and high cholesterol demand,
cells seem to adapt toHDL endocytosis and degradation to supply them-
selves with cholesterol [61]. Is HDL endocytosis therefore a redundant
pathway that only becomes important in pathologic conditions? Impor-
tantly, redundancy is not only found in case of HDL pathways, but may
also exist between lipoprotein classes, where one lipoprotein species
steps in for another: In cells lacking a functional LDL-receptor, SR-BI
mediates both selective and holo-particle uptake from LDL [29,114].
Another hypothesis for an essential function of holo-particle uptake is
cholesterol delivery to distinct cellular pools. In hepatocytes, for instance,
there is evidence for distinct functional cholesterol pools, one for bile-acid
synthesis and one for direct cholesterol secretion into the bile [115]. One
can speculate that HDL endocytosis transports cholesterol to an intracel-
lular pool that is different from the one supplied by selective uptake.
Taken together, the role of HDL uptake and resecretion in cholesterol
homeostasis is still insufﬁciently deﬁned. However, the function of HDL
as a transport vehicle is not restricted to cholesterol. Instead, HDL cargo
comprises a multitude of lipid species, hormones, proteins and nucleic
acids [3]. For instance, HDL can transport microRNAs to target cells
to modulate gene expression [116]. Moreover, at least 50 distinct
proteins are associated with HDL, many of which are related to anti-
inﬂammatory and anti-oxidative functions [117,118]. It is interesting
to hypothesize that HDL endocytosis has a yet elusive role in transfer
of non-lipid cargo. HDL might acquire proteins and microRNAs during
intracellular trafﬁcking, and endocytosis in target cells might be re-
quired for unloading this non-lipid cargo.
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